Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients With Asthma
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients With Asthma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar lavage fluid (BALF) and serum in a dose-dependent manner in normal healthy volunteers (NHV) and in patients with mild to moderate asthma.
Arrowhead Pharmicals, Inc.（納斯達克股票代碼：ARWR）今天宣佈，ARO-RAGE是一種治療哮喘等炎症性肺部疾病的在研藥物 ARO-RAGE 的新中期臨床數據，已在美國胸科學會（ATS）2024年國際會議上公佈。正在進行的1/2期研究的中期結果表明，在正常健康志願者（NHV）和輕度至中度哮喘患者中，使用ARO-RAGE治療可以以劑量依賴的方式降低支氣管肺泡灌洗液（BALF）和血清中的可溶性RAGE（sRage）濃度。